Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 VANCOUVER, British Columbia, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...

Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...

Breathtec Announces Closing of Private Placement Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical...